Literature DB >> 22266379

Older patients (age 65+) report better quality of life, psychological adjustment, and adherence than younger patients 5 years after heart transplant: A multisite study.

Andrea M Shamaskin1, Bruce D Rybarczyk, Edward Wang, Connie White-Williams, Edwin McGee, William Cotts, Kathleen L Grady.   

Abstract

BACKGROUND: Research examining age differences after heart transplant (HT) has focused primarily on morbidity and mortality outcomes, with little emphasis on potential age differences in quality of life and psychosocial outcomes. The objective of the study was to determine whether older patients have more positive adjustment and quality of life several years after HT compared with younger patients.
METHODS: The study recruited 555 patients who were at least 5 years post-HT from 4 United States medical centers. The sample included 165 older patients (≥ 60 years at HT), 300 middle-aged patients (between 45 and 59 years), and 90 younger patients (< 45 years). Of these, 78% were men, 88% were white, and most were well educated (14.04 mean years of education). Outcome measures examined quality of life, social support, mood, coping strategies, stress, health functioning, and adherence. Hypotheses regarding outcomes were derived from incidental findings from the original study.
RESULTS: Statistics included multivariate analyses of covariance, followed by univariate analyses of covariance that controlled for differences in sex, race, years of education, and marital status. Older HT patients were more satisfied with quality of life (p < 0.001) and social support (p = 0.003), had less HT-related stress (p < 0.001), negative affect (p < 0.001), depression (p < 0.001), better overall functioning (p = 0.035), less use of negative coping strategies (p = 0.006), less difficulty with adherence (p < 0.001), and better actual adherence (p < 0.001) than younger and middle-aged HT patients.
CONCLUSIONS: Older patients in this large sample had better quality of life, psychosocial adjustment, and adherence after HT than middle-aged and younger patients. If replicated, this age advantage should at least be considered when assessing age as a criterion for HT clinical decision making and organ allocation policy.
Copyright © 2012 International Society for Heart and Lung Transplantation. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22266379     DOI: 10.1016/j.healun.2011.11.025

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  12 in total

1.  Medical Contraindications to Transplant Listing in the USA: A Survey of Adult and Pediatric Heart, Kidney, Liver, and Lung Programs.

Authors:  Anji Wall; Gun Ho Lee; Jose Maldonado; David Magnus
Journal:  World J Surg       Date:  2019-09       Impact factor: 3.352

2.  The relationship of socio-demographic factors and satisfaction with social support at five and 10 yr after heart transplantation.

Authors:  Connie White-Williams; Kathleen L Grady; David C Naftel; Susan Myers; Edward Wang; Bruce Rybarczyk
Journal:  Clin Transplant       Date:  2012-12-30       Impact factor: 2.863

3.  Assessing the impact of heart failure therapeutics on quality of life and functional capacity.

Authors:  Eldrin F Lewis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2013-08

Review 4.  Psychosocial factors and quality-of-life after heart transplantation and mechanical circulatory support.

Authors:  Emily M Rosenberger; Kristen R Fox; Andrea F DiMartini; Mary Amanda Dew
Journal:  Curr Opin Organ Transplant       Date:  2012-10       Impact factor: 2.640

Review 5.  The value of psychosocial factors in patient selection and outcomes after heart transplantation.

Authors:  Erin E Coglianese; Mekhala Samsi; Max J Liebo; Alain L Heroux
Journal:  Curr Heart Fail Rep       Date:  2015-02

6.  Change in health-related quality of life from before to after destination therapy mechanical circulatory support is similar for older and younger patients: analyses from INTERMACS.

Authors:  Kathleen L Grady; David C Naftel; Susan Myers; Mary Amanda Dew; Gerdi Weidner; John A Spertus; Katharine Idrissi; Hochang B Lee; Edwin C McGee; James K Kirklin
Journal:  J Heart Lung Transplant       Date:  2014-10-31       Impact factor: 10.247

Review 7.  Adherence to immunosuppression in adult heart transplant recipients: A systematic review.

Authors:  Tasmeen Hussain; Keira Nassetta; Linda C O'Dwyer; Jane E Wilcox; Sherif M Badawy
Journal:  Transplant Rev (Orlando)       Date:  2021-09-20       Impact factor: 3.943

8.  Health-Related Quality of Life in Older Patients With Heart Failure From Before to Early After Advanced Surgical Therapies: Findings From the SUSTAIN-IT Study.

Authors:  Kathleen L Grady; Andrew Kao; John A Spertus; Eileen Hsich; Mary Amanda Dew; Duc-Thinh Pham; Justin Hartupee; Michael Petty; William Cotts; Salpy V Pamboukian; Francis D Pagani; Brent Lampert; Maryl Johnson; Margaret Murray; Koji Takeda; Melana Yuzefpolskaya; Scott Silvestry; James K Kirklin; Adin-Cristian Andrei; Christian Elenbaas; Abigail Baldridge; Clyde Yancy
Journal:  Circ Heart Fail       Date:  2022-10-10       Impact factor: 10.447

9.  Factors associated with stress and coping at 5 and 10 years after heart transplantation.

Authors:  Kathleen L Grady; Edward Wang; Connie White-Williams; David C Naftel; Susan Myers; James K Kirklin; Bruce Rybarczyk; James B Young; Dave Pelegrin; Jon Kobashigawa; Robert Higgins; Alain Heroux
Journal:  J Heart Lung Transplant       Date:  2013-04       Impact factor: 10.247

10.  Health-Related Quality of Life in Older Patients With Advanced Heart Failure: Findings From the SUSTAIN-IT Study.

Authors:  Kathleen L Grady; Adin-Cristian Andrei; Christian Elenbaas; Anna Warzecha; Abigail Baldridge; Andrew Kao; John A Spertus; Duc-Thinh Pham; Mary Amanda Dew; Eileen Hsich; William Cotts; Justin Hartupee; Salpy V Pamboukian; Francis D Pagani; Michael Petty; Brent Lampert; Maryl Johnson; Margaret Murray; Koji Takeda; Melana Yuzefpolskaya; Scott Silvestry; James K Kirklin; Clyde Yancy
Journal:  J Am Heart Assoc       Date:  2022-02-12       Impact factor: 6.106

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.